Managed Healthcare Executive

Novel sustained-release DME therapy shows promising results

A novel treatment that uses a disintegrating matrix for sustained release of medication led to improvement in vision and reduced supplemental treatment in patients with diabetic macular edema, ...
Business Wire

Genentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study

– The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with DME treated with Vabysmo who identify as African American, Black, Hispanic and ...

Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) i…

Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases ...
Business Wire

Second Lucentis Phase III Study Meets Primary Endpoint for Improved Vision in Patients with Diabetic Macular Edema (DME)

In RVO, angiogenesis and hyperpermeability can lead to macular edema, the swelling and thickening of the macula. In wet AMD clinical trials, Lucentis administered monthly demonstrated an improvement ...
Morningstar

New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)

PALO ALTO, Calif., Sept. 15, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing ...
Healio

VIDEO: Early drying of intraretinal fluid leads to better vision, anatomic outcomes in DME

Please provide your email address to receive an email when new articles are posted on . SEATTLE — In this Healio Video Perspective from the ARVO meeting, Dolly Shuo-Teh Chang, MD, of Genentech ...
Seeking Alpha

Genentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

– Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment option for patients – – Vision improvements were seen in ...
Nasdaq

Clearside Biomedical's ARCATUS® NDA Accepted for Review in China for Uveitic Macular Edema Treatment

Clearside Biomedical, Inc. announced that the Chinese Center for Drug Evaluation has accepted Arctic Vision's New Drug Application (NDA) for ARCATUS®, a treatment for uveitic macular edema (UME), for ...
Healio

Eylea HD meets primary endpoint of improved vision in phase 3 retinal vein occlusion trial

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Eylea HD improved vision with extended dosing intervals ...
Everyday Health

8 Ways to Ease Anxiety Before an Eye Injection for Diabetic Macular Edema

These injections can restore your eyesight and ward off vision loss. And they aren’t nearly as stressful as you might think. No one really looks forward to getting a shot — and when you’re living with ...
Seeking Alpha

New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)

Meaningful vision gains are rapidly achieved as early as week 4 and more than half of patients in the top two dose levels improved 3-lines or more on the eye chart (≥15 letter gain) A single dose of ...